Impact of Lycium barbarum polysaccharide on apoptosis in Mycoplasma-infected splenic lymphocytes

Bo Huang¹, Wei-kun Zheng²*, Zhi-wei Xu² and Yi-ping Chen²

¹Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, ²Department of Pediatric Infectious Diseases, The Second Affiliated Hospital, Wenzhou, Zhejiang, China

*For correspondence: Email: weikunzheng@yeah.net

Sent for review: 10 May 2017 Revised accepted: 23 August 2017

Abstract

Purpose: To evaluate the effect of Lycium barbarum polysaccharide (LBP) on apoptosis in Mycoplasma-infected splenic lymphocytes (SLs), and the underlying mechanisms.

Methods: SLs isolated from C57BL/6J mice were infected with Mycoplasma. The infected SLs were administered at different concentrations of LBP for 4 h, and the proportions of apoptotic cells and levels of relative reactive oxygen species (ROS) were determined by flow cytometry. The expressions of pro-apoptotic genes and endogenous antioxidant enzymes were investigated by real-time polymerase chain reaction (RT-PCR) and Western blotting.

Results: LBP treatment produced dose-dependent reductions in apoptotic ratio and intracellular ROS levels of SLs (p < 0.05). In addition, the expressions of pro-apoptotic genes were decreased by LBP treatment with respect to mRNA and protein levels (p < 0.05). In contrast, mRNA and protein levels of anti-apoptotic factor Bcl-2 were significantly increased in a dose-dependent manner (p < 0.05). Furthermore, RT-PCR and Western blot results demonstrated that the expression levels of mRNA and proteins in Nrf2, HO-1 and NQO1 were up-regulated by Mycoplasma infection (p < 0.01), and further increased by LBP treatment (p < 0.05).

Conclusion: LBP exerts a hyperactive antioxidant response encoded by Nrf2 to protect SLs from apoptosis induced by ROS-related oxidative damage after Mycoplasma infection. These results suggest that LBP may serve as a beneficial and dietary anti-Mycoplasma and anti-apoptotic agent.

Keywords: Lycium barbarum polysaccharide, Splenic lymphocytes, ROS, Caspase-3, Bax, Nrf2

INTRODUCTION

Mycoplasma has significant impacts on many human diseases [1]. Immune responses are believed to play roles in protection from Mycoplasma diseases [1]. In Chinese traditional medicine, the use of Lycium barbarum as a functional food for promoting immunity and longevity were documented as far back as 2,800 BC [2]. Studies have shown that Lycium barbarum polysaccharide (LBP), a major active component of Lycium barbarum, attenuates cytotoxicity, lowers blood glucose, enhances immunity, and also possesses anti-cancer properties [3-5]. Apoptosis is closely associated with lymphocyte development and homeostasis [6]. Enhanced or inhibited apoptosis in lymphocyte can lead to immunodeficiency or autoimmunity, or lymphoma [6]. LBP plays an important role in lymphocyte proliferation and cytokine production [7,8]. A recent study reported that LBP has beneficial effects on spermatogenesis through regulation of apoptosis and antioxidant activity in diabetic male mice [9]. However, little is known about the effect of LBP on apoptosis in lymphocytes.
Reactive oxygen species (ROS) have been considered as messengers of phagocytes involved in defense against pathogen invasion [10]. They are involved in lymphocytes activation, hypo-responsiveness, and apoptosis [10]. Recent studies indicate that LBP has antioxidant properties [9,11]. Thus, this study was aimed at investigating the effects of LBP on apoptotic signaling induced by ROS-related oxidative damage in splenic lymphocytes (SLs) after Mycoplasma infection.

**EXPERIMENTAL**

**Mycoplasma species**

*Mycoplasma* (MP) species (ATCC 15488, Ziker Biotech, China) was cultured in modified Friis broth containing 2.5 % CO₂ at 37 °C. The culture medium was centrifuged at 18,000 g for 20 min at 4 °C, to harvest the *Mycoplasma*. The cells were washed thrice in PBS (pH 7.4), and suspended in RPMI 1640 medium. It was previously reported that at 540 nm, an absorbance of 0.2 was equivalent to 10⁶ colony-forming units per ml (CFU/mL) of *Mycoplasma* [12]. Thus, the concentration of *Mycoplasma* was determined spectrophotometrically at 540 nm.

**LBP isolation**

Water extraction and ethanol precipitation were employed to extract LBP from *Lycium barbarum* fruit. Dried fruits of *Lycium barbarum* were ground to fine powder and extracted in water at 4 °C overnight. The *Lycium barbarum* residue was then extracted three times in boiling water. Then, the aqueous extract was concentrated and then extracted three times in boiling water. Then, the precipitate was dried to obtain the crude LBP, which was then purified using DEAE-cellulose ion exchange chromatography. Prior to administration, the LBP was dissolved in PBS and filtered through a 0.22 μm filter.

**Cell culture and grouping**

Splenic lymphocyte cell line (obtained from ATCC, USA) was cultured in RPMI-16 40 medium supplemented with 10 % fetal bovine serum (FBS) at 37 °C in a 5% CO₂-humidified incubator. The cells were divided into 7 groups: control group, and six *Mycoplasma* (20 cfu/mL) groups, containing different LBP concentrations as follows: 0 (vehicle), 20, 50, 100, 200, and 400 μg/mL (coded MP, LBP 20, LBP 50, LBP 100, LBP 200 and LBP 400, respectively). Cellular apoptosis was determined 4 h after treatment.

**Flow cytometry analysis**

SLs were harvested and washed twice with PBS. Then, the cell pellet was re-suspended in washing buffer. For the apoptosis analysis, the cells were stained with PI dye at 4 °C for 30 min, followed by examination using a FACSCanto II cytometer (BD Biosciences, Germany). The percentage of apoptotic cells was calculated.

In order to determine the level of ROS, SLs were incubated with fluorescent probe DCFH-DA (10 μM) at 37 °C for 30 min. Then, after washing, intracellular ROS were quantified by FACSCanto II cytometer (BD Biosciences, Germany).

**Quantitative real-time PCR**

SLs were washed with PBS and RNA was extracted using RNeasy Plus Micro Kit (QIAGEN, USA), followed by cDNA synthesis using SuperScript® IV First-Strand Synthesis System (Invitrogen, USA). PCR primers (with sequences) of the target genes were as follows: β-Actin (internal control): 5'-TGC TGT GTC CCC ATC TAT CG -3' (forward) and 5'-TTG GTG ACA ATA CCG TGT TCA -3' (reverse); Caspase-3: 5'-TGG CCC TCT TGA ACT GAA AG -3' (forward) and 5'-GCC AGA GTA CCT GAA CC -3' (reverse); BAX: 5'-TCC TCA TCG CCA TGC TCA T -3' (forward) and 5'-CCT TGG TCT GGA AGC AGA AGA -3' (reverse); Bcl-2: 5'-GAT GAC CGA GTA CCT GAA CC -3' (forward) and 5'-CAG GAG AAA TCG AAC AAA GGC -3' (reverse); Nrf2: 5'-GAG GGT A TG AAG ACA TTG AG -3' (forward) and 5'-AAT TCG AGT GAA GAT GAA GGC AAC -3' (reverse); HO-1: 5'-AAG GGA GGA TTG GAC CGA GCT GGA A -3' (forward) and 5'-AAT TCG AGT GAA GAT GAA GGC AAC -3' (reverse); NQO1: 5'-GTA TTG AGT TCG AGT GAA GAT GAA GGC AAC -3' (reverse); Caspase-3: 5'-TGC TGT GTC CCC ATC TAT CG -3' (forward) and 5'-TTG GTG ACA ATA CCG TGT TCA -3' (reverse); and antioxidant enzyme genes (Nrf2, HO-1, and NQO1). Amplification conditions were as follows: 95 °C, 2 min; 30 cycles of 95 °C, 30 s, 65 °C, 30 s, 72 °C, 1 min; 72 °C, 5 min. The relative quantification of target genes was calculated by ΔΔCT method.

**Western blot analysis**

Cells were lysed in an ice-cold hypotonic lysis buffer (containing proteinase inhibitor cocktail and PMSF) and centrifuged at 10,000 rpm at 4 °C for 10 min. The supernatant was collected and used as protein extracts.

**Amplification conditions** were as follows: 95 °C, 2 min; 30 cycles of 95 °C, 30 s, 65 °C, 30 s, 72 °C, 1 min; 72 °C, 5 min. The relative quantification of target genes was calculated by ΔΔCT method.
°C for 3 min. The protein concentration was measured using BCA Protein Assay reagent kit (Thermo Fisher Scientific, USA). The cell lysates (20 μg of protein) were subjected to 10% SDS-PAGE. Then, the gel was electro-transferred onto a PVDF membrane. After blocking with 5% skimmed milk, the membrane was successively incubated with anti Caspase-3, Bax, Bcl-2, Nrf2, HO-1, and NQO1 primary antibodies (1:1000; Abcam, USA) and goat anti-rabbit IgG-HRP secondary antibody (1:2000; Abcam, USA). Bands were detected by ECL kit (Thermo Fisher Scientific, USA). Target gene expression levels were normalized with an internal control (β-actin).

Statistical analysis

All data are presented as mean ± standard deviation (SD). For multiple group comparisons, one-way analysis of variance (ANOVA) and appropriate post-hoc analysis were performed using a statistical software package (Prism5, USA). *P < 0.05 and **P < 0.01 were considered statistically significant.

RESULTS

LBP prevented SLs apoptosis

The LBP-treated groups exhibited dose-dependent reductions in the apoptotic ratio of SLs when compared to the MP-infected group (Figure 1). When the LBP concentration reached 100 μg/mL, the apoptotic ratio of SLs was significantly decreased relative to the MP-infected group (*P < 0.05). The apoptotic ratio in the 400 μg/mL LBP treated group was decreased to a level similar to the control group. These data indicate that LBP is an effective anti-apoptotic agent in SLs.

Figure 1: Effect of LBP treatment on apoptosis in SLs. (A) Apoptosis of Mycoplasma-infected SLs (b) and SLs treated with vehicle (a), 20 (c), 50 (d), 100 (e), 200 (f), and 400 (g) μg/mL LBP at 4 h was evaluated using PI staining and flow cytometry analysis. (B) Quantitative analysis of the apoptotic cells under different treatment conditions; **P < 0.01, versus MP group; *P < 0.05, versus control group; #P < 0.01, versus the control group; Results are presented as mean ± SD of three experiments. MP = Mycoplasma; LBP = Lycium barbarum polysaccharide

Huang et al
LBP prevented accumulation of intracellular ROS

Flow cytometry analysis showed a dose-dependent decrease in intracellular levels of ROS in SLs. When the LBP concentration reached 400 μg/mL, ROS levels were significantly decreased when compared to the MP group ($p < 0.05$, Figure 2). These results indicate that ROS clearance may be a mechanism involved in the protective effect of LBP on the apoptosis of mycoplasma-infected SLs.

LBP regulated the expressions of pro-apoptotic genes

The expressions of pro-apoptotic genes, caspase-3 and Bax, were decreased by LBP treatment at both mRNA and protein levels. In the 200 and 400 μg/mL groups, the relative expressions of these genes decreased significantly when compared with the MP group ($p < 0.01$, Figure 3). In contrast, both mRNA and protein levels of the anti-apoptotic factor Bcl-2 were significantly increased in a dose-dependent manner when compared with the 200 and 400 μg/mL MP groups ($p < 0.01$).

Figure 2: Effect of LBP treatment on ROS production. (A) ROS levels of Mycoplasma infected SLs (b) and SLs treated with 0 (vehicle) (a), 20 (c), 50 (d), 100 (e), 200 (f), and 400 (g) μg/mL LBP at 4 h were evaluated using DCFH-DA fluorescence by flow cytometry. (B) The geometric mean of fluorescence ± SD; **$p < 0.01$, versus the MP group; *$p < 0.05$, versus the control group; MP = mycoplasma; LBP = Lycium barbarum polysaccharide
Figure 3: Effect of LBP on the expression of pro-apoptotic genes. (A) Relative mRNA expression of caspase3, Bax, and Bcl-2 were determined by RT-PCR. (B) Bands of caspase3, Bax, and Bcl-2 determined by Western blotting. (C) Quantitative analysis of Western blot result; *p < 0.05, versus the MP group; **p < 0.01, versus the MP group; #p < 0.05, versus the control group; MP = Mycoplasma; LBP = Lycium barbarum polysaccharide

**LBP up-regulated antioxidant enzymes through Nrf2 signaling pathway**

Results of qPCR and Western blot show that the mRNA and protein levels of Nrf2 were significantly up-regulated by Mycoplasma infection (p < 0.01 when compared with the control group. Figure 4). LBP treatment for 4 h further increased the Nrf2 expressions, when compared with the MP group (for mRNA levels: p < 0.01 in the 50 to 400 μg/mL groups; for protein levels: p < 0.01 in the 400 μg/mL group), HO-1 (for mRNA levels: p < 0.01 in the 200 to 400 μg/mL groups; for protein levels: p < 0.01 in the 50 to 400 μg/mL groups), and NQO1 (for mRNA levels: p < 0.01 in the 50 to 400 μg/mL groups; for protein levels: p < 0.01 in the 200 to 400 μg/mL groups; Figure 4). These results support the anti-apoptotic role and ROS-clearing effects of LBP.

**DISCUSSION**

In this study, Mycoplasma-infected SLs were used to investigate the role of LBP in antioxidant defense against immunologic injury. It was found that Mycoplasma infection increased apoptosis and ROS accumulation in SLs. However, LBP treatment reduced the ROS levels, increased the activation of Nrf2 pathway, and inhibited apoptotic signals. A growing body of evidence indicate that LBP and Lycium barbarum have a variety of immuno-modulatory functions. Some researchers reported that LBP can induce phenotypic and functional maturation of dendritic cells via NFκB signaling pathways [13,14]. It has been shown that LBP can act as an adjuvant for the generation of Tfh cells to enhance T cell-dependent antibody responses [15]. It has also been demonstrated that LBP can promote cytokine secretion in macrophages, Th1, and Th2 [16]. Researchers have consistently shown that LBP significantly induces proliferation of T lymphocytes [4,17]. However, not much was hitherto know about the anti-apoptotic and antioxidant effects of LBP in lymphocytes. To the best of our knowledge, the present study is the first to demonstrate the anti-apoptotic property of LBP in SLs through the Nrf2 pathway, thereby providing a deeper understanding of its beneficial properties in immunocytes.
Figure 4: Effect of LBP on expression of antioxidant enzyme genes. (A) Relative mRNA expression of Nrf2, HO-1, and NQO1 were determined by RT-PCR. (B) Bands of Nrf2, HO-1, and NQO1 determined by Western blotting. (C) Quantitative analysis of Western blot results; * p < 0.05, versus MP group; ** p < 0.01, versus MP group; # p < 0.05, versus control group; MP = Mycoplasma; LBP = Lycium barbarum polysaccharide

Numerous studies have reported that the Nrf2 signaling pathway plays a critical role in cellular defense against oxidative stress. Some researchers used Keap1-deficient mice and found that T-cell–specific augmentation of Nrf2 increased antioxidant response and reduced intracellular cytokine production by T-cells [18]. Nrf2-KO mice developed inflammatory lesions and autoimmune syndromes, and decreases in expressions of HO-1 and NQO1 [19]. HO-1 and NQO1 are two well-recognized downstream factors of the Nrf2 signaling pathway. HO-1 is as a potent radical scavenger known to protect cells against oxidative stress [20]. Studies with HO-1 knockout mice which exhibit increased susceptibility to oxidative insults proved that HO-1 is involved in the endogenous defense against oxidative stress [20]. NQO1 is a flavoprotein which prevents the participation of quinones in redox cycling, thereby sequestering ROS [21]. However, there is lack of data on the role of Nrf2 signaling pathway in SLs infected with Mycoplasma. Thus, the effect of Mycoplasma on activation of Nrf2 and its downstream antioxidant enzymes (HO-1 and NQO1) was investigated in the present study. The results obtained suggest that the Nrf2 pathway is involved in the survival of Mycoplasma-infected SLs, and that LBP treatment protects the infected SLs through the clearance of ROS.

CONCLUSION

The results of this study indicate that LBP can protect Mycoplasma-infected SLs from ROS-induced apoptosis through a mechanism involving a hyperactive antioxidant response encoded by Nrf2. This finding provides evidence to show that LBP may serve as a beneficial and dietary anti-Mycoplasma and anti-apoptotic agent.

DECLARATIONS

Acknowledgement

We are grateful to our institutes for their assistance during the preparation of this manuscript.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

Trop J Pharm Res, September 2017; 16(9): 2132
**Open Access**

This is an Open Access article which uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/rea d), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

**REFERENCES**

1. Citti C, Blanchard A. Mycoplasmas and their host: emerging and re-emerging minimal pathogens. Trends Microbiol 2013; 21(4): 196-203.
2. Mocan A, Vlase L, Vodnar DC, Bischin C, Hangaru D, Gheolduu AM, Opran R, Silaghi-Dumitrescu R, Crisan G. Polyphenolic Content, Antioxidant and Antimicrobial Activities of Lycium barbarum L. and Lycium chinense Mill. Leaves. Molecule 2014; 19(7): 10056-10073.
3. Huyan T, Li Q, Yang H, Jin ML, Zhang MJ, Ye LJ, Li J, Huang QS, Yin DC. Protective effect of polysaccharides on simulated microgravity-induced functional inhibition of human NK cells. Carbohydr Polym 2014; 101: 819-827.
4. Chen Z, Tan BKH, Chan SH. Activation of T lymphocytes by polysaccharide-protein complex from Lycium barbarum L. Int Immunopharmacol 2008; 8(12): 1663-1671.
5. Miao Y, Xiao B, Jiang Z, Guo Y, Mao F, Zhao J, Huang X, Guo J. Growth inhibition and cell-cycle arrest of human gastric cancer cells by Lycium barbarum polysaccharide. Med Oncol 2010; 27(3): 785-790.
6. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002; 109: S97-S107.
7. Gan L, Zhang SH, Liu Q, Xu HB. A polysaccharide-protein complex from Lycium barbarum upregulates cytokine expression in human peripheral blood mononuclear cells. Eur J Pharmacol 2003; 471(3): 217-222.
8. Gan L, Zhang SH, Yang XL, Xu HB. Immunomodulation and antitumor activity by a polysaccharide-protein complex from Lycium barbarum. Int Immunopharmacol 2004; 4(4): 563-569.
9. Shi GJ, Zheng J, Wu J, Qiao HQ, Chang Q, Niu Y, Sun T, Li YY, Yu JQ. Beneficial effects of Lycium barbarum polysaccharide on spermatogenesis by improving antioxidant activity and inhibiting apoptosis in streptozotocin-induced diabetic male mice. Food Funct 2017; 8, 1215-1226.
10. Belkov AV, Schraven B, Simeoni L. T cells and reactive oxygen species. J Biomed Sci 2015; 22: 85.
11. Liang B, Lin ML, Liu HB. Water-soluble polysaccharide from dried Lycium barbarum fruits: isolation, structural features and antioxidant activity. Carbohydr Polym 2011; 83(4): 1947-1951.
12. Punyapornwithaya V, Fox LK, Gay GM, Hancock DD, Allredge JR. Short communication: The effect of centrifugation and resuspension on the recovery of Mycoplasma species from milk. J Dairy Sci 2009; 92(9): 4444-4447.
13. Zhu J, Zhao LH, Zhao XP, Chen Z. Lycium barbarum polysaccharides regulate phenotypic and functional maturation of murine dendritic cells. Cell Biol Int 2007; 31(6): 615-619.
14. Zhu J, Zhang Y, Shen Y, Zhou H, Yu X. Lycium barbarum polysaccharides induce Toll-like receptor 2- and 4-mediated phenotypic and functional maturation of murine dendritic cells via activation of NF-κappa β. Mol Med Rep 2013; 8(4): 1216-1220.
15. Su CX, Duan XG, Liang LJ, Feng W, Zheng J, Fu XY, Yan YM, Ling H, Wang NP. Lycium barbarum polysaccharides as an adjuvant for recombinant vaccine through enhancement of humoral immunity by activating Th1 cells. Vet Immunol Immunopathol 2014; 158(1-2): 98-104.
16. Bo R, Zheng S, Xing J, Luo L, Niu Y, Huang Y, et al. The immunological activity of Lycium barbarum polysaccharides liposome in vitro and adjuvanticity against PCV2 in vivo. Int J Biol Macromol 2016; 85: 294-301.
17. Du G, Liu L, Fang J. Experimental study on the enhancement of murine splenic lymphocyte proliferation by Lycium barbarum glycopeptide. J Huazhong Univ Sci Technolog Med Sci 2004; 24 (5): 518-520, 527.
18. Noel S, Martina MN, Bandapalle S, Racusen LC, Pottetti HR, Hamad AR, Reddy SP, Rabb HT. Lymphocyte-Specific Activation of Nrf2 Protects from AKI. J Am Soc Nephrol 2015; 26(12): 2989-3000.
19. Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 2006; 168(6): 1960-1974.
20. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA 1997; 94(20): 10925-10930.
21. van Horssen J, Schreibelt G, Bö L, Montagne L, Drkarch B, van Muuswinkel FL, de Vries HE NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic Biol Med 2006; 41(2): 311-317.